IP Verse

Products And Compositions - EP3607069

The patent EP3607069 was granted to Silence Therapeutics on Nov 2, 2022. The application was originally filed on Apr 5, 2018 under application number EP18715706A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3607069

SILENCE THERAPEUTICS
Application Number
EP18715706A
Filing Date
Apr 5, 2018
Status
Granted And Under Opposition
Sep 30, 2022
Grant Date
Nov 2, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMMELBURGJul 31, 2023FISH & RICHARDSON PCADMISSIBLE

Patent Citations (27) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2005080246
INTERNATIONAL-SEARCH-REPORTWO2007112414
INTERNATIONAL-SEARCH-REPORTWO2009002944
INTERNATIONAL-SEARCH-REPORTWO2010078536
INTERNATIONAL-SEARCH-REPORTWO2013074974
INTERNATIONAL-SEARCH-REPORTWO2013075035
INTERNATIONAL-SEARCH-REPORTWO2016085852
INTERNATIONAL-SEARCH-REPORTWO2016161388
INTERNATIONAL-SEARCH-REPORTWO2017030973
OPPOSITIONWO2007022369
OPPOSITIONWO2007112414
OPPOSITIONWO2009002944
OPPOSITIONWO2009073809
OPPOSITIONWO2010039548
OPPOSITIONWO2012037254
OPPOSITIONWO2013074974
OPPOSITIONWO2015006740
OPPOSITIONWO2015188194
OPPOSITIONWO2016085852
OPPOSITIONWO2017059223
OPPOSITIONWO2017214112
OPPOSITIONWO2018027106
OPPOSITIONWO2018132432
OPPOSITIONWO2018140920
OPPOSITIONWO2018185241
OPPOSITIONWO2019051402
OPPOSITIONWO2019055633

Non-Patent Literature (NPL) Citations (4) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- SHEN WEN ET AL, "2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF", GB, vol. 43, no. 9, doi:10.1093/nar/gkv298, ISSN 0305-1048, (20150519), pages 4569 - 4578, NUCLEIC ACIDS RESEARCH, URL: https://academic.oup.com/nar/article-pdf/43/9/4569/5153015/gkv298.pdf, XP055863433
OPPOSITION- Brown Bob D, "We Do GalNAc and So Can You! Dicerna GalNAc-DsiRNA-EX Update", Dicerna pharmaceutics, (20160101), pages 1 - 22, XP093072936-
OPPOSITION- Shen Wen, Liang Xue-Hai, Sun Hong, Crooke Stanley T., "2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF", Nucleic Acids Research, GB , (20150519), vol. 43, no. 9, doi:10.1093/nar/gkv298, ISSN 0305-1048, pages 4569 - 4578, XP055863433
OPPOSITION- Shen Wen, Liang Xue-Hai, Sun Hong, Crooke Stanley T., "2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF", Nucleic Acids Research, Oxford University Press, GB, GB , (20150519), vol. 43, no. 9, doi:10.1093/nar/gkv298, ISSN 0305-1048, pages 4569 - 4578, XP055863433

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents